Re: Gonadotropin Releasing Hormone

August 26, 2010

I am not sure is this is about the same thing your thinking about but here is a

cut and paste from Dr. 's forum this guy is a Dr. with low T posting this a

cut and poste from this link.

http://www.musclechatroom.com/forum/showthread.php?t=13861 & highlight=GnRH

====================================================

#1 05-04-2010

Dadnatron

Senior Member Join Date: Aug 29, 2009

Posts: 405

Certain GnRH Agonists May Increase Risk Of Diabetes, Heart Attack, FDA Warns.

--------------------------------------------------------------------------------

Certain GnRH Agonists May Increase Risk Of Diabetes, Heart Attack, FDA Warns.

The AP (5/4) reports, " The Food and Drug Administration is looking into data

suggesting a group of prostate cancer drugs increase the risk of diabetes and

heart disease. " According to Dow Newswire (5/3, Dooren), the drugs are

meant to reduce the levels of male hormones and are marketed under several brand

names.

They are also part of " a family of drugs known as gonadotropin-releasing hormone

(GnRH) agonists, which are used for hormone deprivation therapy to treat men

with prostate cancer, " the Los Angeles Times (5/3, Maugh) " Booster Shots "

reported. " Some of the drugs are also used by women to manage pain caused by

endometriosis, to improve anemia associated with uterine fibroids before a

hysterectomy, and for palliative treatment of advanced breast cancer. " They are

also " used in some children to treat a form of precocious puberty, " but " there

is no evidence suggesting an increased risk in women or children, the agency

said. "

In men, however, the FDA " says doctors should be aware of the potential risks of

GnRH agonists, and carefully consider the benefits and risks of these drugs when

deciding on treatment for prostate cancer patients, " HealthDay (5/3, Preidt)

reported. " Based on initial findings from a preliminary and ongoing analysis of

several studies, " the agency also suggested that " management of cardiovascular

risk factors -- including smoking, as well as increases in blood pressure,

cholesterol, blood sugar and weight -- should be stressed, " and those " taking

GnRH agonists should not stop the therapy unless instructed by their healthcare

provider. "

MedPage Today (5/3, Petrochko) reported that the risks of " diabetes, myocardial

infarction, stroke, and sudden death " were first " detailed earlier this year in

a joint advisory issued by the American Heart Association, the American

Urological Association, and the American Cancer Society. " GnRH agonists

" currently on the market include leuprolide acetate (Lupron, Viadur, Eligard,

and various generics), goserelin acetate (Zoladex), triptorelin pamoate

(Trelstar), histrelin acetate (Vantas), and nafarelin acetate (Synarel). "

Bloomberg News (5/4, Larkin) also covers the story.

Dadnatron

View Public Profile

Send a private message to Dadnatron

Find all posts by Dadnatron

Add Dadnatron to Your Contacts

#2 05-04-2010

Dadnatron

Senior Member Join Date: Aug 29, 2009

Posts: 405

Re: Certain GnRH Agonists May Increase Risk Of Diabetes, Heart Attack, FDA

Warns.

--------------------------------------------------------------------------------

FDA says certain prostate cancer drugs may increase risk of diabetes,

cardiovascular disease

May 3, 2010 | 10:08 am

The Food and Drug Administration said Monday it is investigating the safety of a

family of drugs known as gonadotropin-releasing hormone agonists, which are used

for hormone deprivation therapy to treat men with prostate cancer. The agency

said small studies have suggested that the drugs might be associated with an

increased risk of diabetes and cardiovascular disease, although the evidence is

not conclusive and agency scientists are still investigating.

The drugs, commonly called GnRH agonists or luteinizing-releasing hormone

agonists, suppress the production of testosterone, the male hormone that

stimulates the growth of many prostate tumors, by the testicles. Producing what

is called chemical castration, they are an alternative to surgical castration,

which is also used. They are not a cure for prostate cancer, but can

significantly slow tumor growth or even shrink tumor size. Some of the drugs are

also used by women to manage pain caused by endometriosis, to improve anemia

associated with uterine fibroids before a hysterectomy and for palliative

treatment of advanced breast cancer. They are also used in some children to

treat a form of precocious puberty. There is no evidence suggesting an increased

risk in women or children, the agency said.

Most of the studies reviewed by the FDA reported small but statistically

significant increased risks of diabetes and heart disease, the agency said. But

the data have a variety of shortcomings, including poor definition of what types

of androgen deprivation therapy were used, the amount of drug used and for how

long, and a lack of data about the patients' risk factors for the disease before

therapy began, among other problems. Those deficiencies made it difficult to

establish a cause-and-effect relationship.

While the FDA investigates the drugs, it said that patients should not stop

taking them. Physicians planning to prescribe them should evaluate the risks and

benefits and, when they are prescribed, monitor the patients for precursors of

diabetes, as well as high blood pressure, high cholesterol and increased weight

gain.

The drugs involved include:

-- Lupron, manufactured by Abbott Laboratories of Abbott Park, Ill.

-- Eligard, manufactured by Sanofi-Aventis of Bridgewater, N.J.

-- Synarel, manufactured by Pfizer of New York City

-- Trelstar, manufactured by Pharmaceuticals of Corona

-- Vantas, manufactured by Endo Pharmaceuticals of Chadds Ford, Penn.

-- Viadur, manufactured by Bayer Pharmaceuticals of Wayne, N.J.

-- Zoladex, manufactured by AstraZeneca of Wilmington, Del.

This year, an estimated 203,415 new cases of prostate cancer will be diagnosed

and about 28,372 men will die from it, according to the Centers for Disease

Control.

-- H. Maugh II

Co-Moderator

Phil

> From: Vergel <nelsonvergel@...>

> Subject: Gonadotropin Releasing Hormone

>

> Date: Thursday, August 26, 2010, 4:09 PM

>

http://www.pharmacorama.com/en/Sections/Hypothalamic_and_pituitary_hormones_2.ph\

p

>

> Has anyone tried this? I am about to get some

> compounded. I will try it for the

> first time.

>

> Even with testosterone at normal levels, I am only

> ejaculating one drop even if

> I do not orgasm in days. I hope this hormone can

> increase my FSH (and LH)

> somewhat to see if I have any more ejaculate. I will

> also monitor my free

> testosterone and estradiol to see its effect on these two

> hormones (increased LH

> should also increase testosterone)

> Regards,

>

> Vergel

>

August 26, 2010

Phil

The link you sent was for agonists of the hormone I referred to, meaning they

block the effect of the hormone (for prostate cancer). So, it is not what am

referring to. Thanks

Regards,

Vergel

PoWeRUSA.org

________________________________

From: philip georgian <pmgamer18@...>

Sent: Thu, August 26, 2010 3:25:35 PM

Subject: Re: Gonadotropin Releasing Hormone